Biora Therapeutics, Inc. (NASDAQ:BIOR) Sees Significant Increase in Short Interest

Biora Therapeutics, Inc. (NASDAQ:BIOR) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 201,800 shares, an increase of 43.3% from the October 15th total of 140,800 shares. Based on an average daily volume of 50,100 shares, the short-interest ratio is presently 4.0 days. Currently, 4.8% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $150.00 price objective on shares of Biora Therapeutics in a research note on Tuesday, August 13th.

Biora Therapeutics Trading Down 10.9 %

Shares of Biora Therapeutics stock traded down $0.26 on Friday, hitting $2.12. 187,697 shares of the company traded hands, compared to its average volume of 40,747. The stock’s 50 day moving average price is $4.73 and its 200-day moving average price is $6.04. Biora Therapeutics has a 52 week low of $2.03 and a 52 week high of $19.90. The company has a market cap of $7.80 million, a PE ratio of -0.04 and a beta of 1.27.

Biora Therapeutics (NASDAQ:BIOR) last posted its quarterly earnings results on Monday, August 12th. The company reported ($3.50) earnings per share for the quarter, beating the consensus estimate of ($4.50) by $1.00. The company had revenue of $0.32 million for the quarter. As a group, research analysts anticipate that Biora Therapeutics will post -12.45 EPS for the current fiscal year.

Biora Therapeutics Company Profile

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.